The New York Gold Institute (NYBC) is the first group that collects blood in the United States to receive plasma from COVID-19 patients for use as a potential cancer treatment.
Before the antibiotic transformed this virus, it became commonplace to treat bacterial infections by donating the blood of people who were hospitalized to those struggling with the infection. Attempts have been made to use this approach against infection such as H1N1 virus, SARS and MERS, with unsuccessful success. Some patients benefit, but others do not and doctors do not fully understand the cause. But during a pandemic such as COVID-19, plasma therapies can provide a sense of relief as therapies are enhanced.
The idea is simple, and is designed with the aim of infinite immunity. People who have recovered from COVID-19 infection, probably because they have their immune system triggered a strong immune response to SARS-CoV-2, the virus that causes the disease. As an integral part of their response, they encode antibodies, including major antibodies and specific antibodies that are directly involved in the protein found in SARS-CoV-2. In theory, these immunizations may be taken from a recovered COVID-19 patient, and to be associated with a recently infected patient. Bruce Sachais, chief executive of New York Blood Hospital, said: “If you give it to someone who is sick, the bacteria can help patients get the disease easily and easily. ” Business Center.
While the drug is still being tested, the US Food and Drug Administration on March 24 allows physicians to use plasma from cured patients to treat those with or without CVID-19 disease. here ”under the approval process. The doctors will be able to use the FDA for use in their patients, and the agency will review requests promptly and determine the case based on the case.
Sachais said NYBC is ready to begin receiving blood transfusions from its responders who have tested positive for a viral infection, and have met certain requirements to make sure their plasma is safe. It is likely that those who make the first donations will come from the hospitals that have successfully treated patients, and the treatment provided will go back to those hospitals to care for their patients. But Sachais said he is working with other blood centers and hospitals to create a system for keeping donated plasma between them.
At present, each patient can take one plasma dose, which is about 200-250 centimeters. But because the amount of antibody in donors may vary, researchers are currently looking for ways to provide more energy and consistency. Accelerator BioSolutions, a biopharmaceutical company in Maryland, is working on a way to track gluten from cured patients and use that to create toxic antibodies, for example. That way, scientists do not have to choose donors with the best antibiotics, and they can pick up Plasma eggs from one of the hospital’s most trusted clinics, said Laura Saward, chief of the business’s therapeutic division.
The company is also looking for alternatives to antibiotics – in particular, horses. It relies on horses to provide treatments for botulism, and its researchers are adapting this approach to producing human plasma based on COVID-19. The horses are exposed to fragments of SARS-CoV-2 and cause immunity to the tumor, and because of the size of the animals, the plasma they provide can help treat more than one patient at a time. “We can quickly get to the point where we have a lot of horses that donate blood weekly to help develop these antibiotics,” Saward said. “It is thought that small plains of plaque will have an effect on humans because there will be high levels of blood thinning in small doses.”
Because Emergent technology involves more processes than controlling plasma from one person and assigning it to another, Saward says human testing and plasma testing will take months. The company plans to begin testing its products in humans by the end of the summer.
Sachais is also thinking of ways to treat the old tumor in small doses of plasma. But in the meantime, as more and more people are receiving plasma units offered by blood donors like NYBC, doctors will learn more about the type of supplement it provides, and determine if it can help prevent it. infection in the risk of people like health workers. “We are working with national organizations to share our experiences with them,” he said, “and the possibility of sharing plasma products as time goes on, depends on how well the disease is progressing, to ensure that it is collect the product and distribute it where needed. ”
Summary of Coronavirus. Everything you need to know about the spread of COVID-19 in the world
For your safety, we sent a confirmation email to the address you entered. Click the link to confirm your subscription and start receiving newsletters. If you do not get confirmation within 10 minutes, please check your folder.